News >

Mamounas Sheds Light on Adjuvant Endocrine Therapy in Breast Cancer

Angelica Welch
Published: Friday, Sep 01, 2017

Terry Mamounas, MD

Terry Mamounas, MD
Recent findings have suggested that 10 years versus 5 years of adjuvant hormone therapy reduces recurrence in women with primary breast cancer; however, the topic has been widely debated among researchers.

For example, results of the NSABP B-42 clinical trial, which were presented at the 2016 San Antonio Breast Cancer Symposium, found that extending letrozole therapy in women with early-stage, hormone receptor (HR)–positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival. However, data also showed that prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x